Sentiment Trading

Alnylam Pharmaceuticals Inc. exceeded Wall Street expectations in Q1 2025, driven by strong revenue and regulatory milestones, positioning the company as a key player in the development of innovative RNAi therapeutics.

Alnylam Pharmaceuticals has received a positive opinion from the European Medicines Agency’s CHMP for its RNA interference therapeutic, vutrisiran, for the treatment of ATTR amyloidosis with cardiomyopathy.